The genetic epidemiology of neurodegenerative disease
Open accessThe DOI matches its Crossref record; 103 of the 106 references it cites were found in a registry or an index.
Abstract
Gene defects play a major role in the pathogenesis of degenerative disorders of the nervous system.In fact, it has been the very knowledge gained from genetic studies that has allowed the elucidation of the molecular mechanisms underlying the etiology and pathogenesis of many neurodegenerative disorders.In this review, we discuss the current status of genetic epidemiology of the most common neurodegenerative diseases: Alzheimer disease, Parkinson disease, Lewy body dementia, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington disease, and prion diseases, with a particular focus on similarities and differences among these syndromes. The complexities of common diseasesFamilial aggregation had been recognized as a prominent characteristic of many neurodegenerative disorders decades before the underlying molecular genetic or biochemical properties were known.It was often the identification of specific, disease-segregating mutations in previously unknown genes that directed the attention to certain proteins and pathways that are now considered crucial in the pathogenesis of these diseases.These include mutations in the β-amyloid (Aβ) precursor protein, causing Alzheimer disease (AD); in α-synuclein, causing Parkinson disease (PD); or in microtubule-associated protein tau, causing frontotemporal dementia (FTD) with parkinsonism.Another feature observed in most common neurodegenerative diseases -as well as in other common disorders -is a dichotomy between familial (rare) and seemingly nonfamilial (common) forms.The latter are also frequently described as "sporadic" or "idiopathic," although there is a growing body of evidence suggesting that a large proportion of these cases are also significantly influenced by genetic factors.These risk genes are likely to be numerous, displaying intricate patterns of interaction with each other as well as with nongenetic variable, and -unlike classical Mendelian ("simplex") disorders -exhibit no simple or single mode of inheritance.Hence, the genetics of these diseases has been labeled "complex."A popular conception regarding the genetic makeup of complex diseases is the "common disease/common variant" (CD/CV) hypothesis (1).According to this theory common disorders are also governed by common DNA variants (such as single nucleotide polymorphisms.These variants significantly increase disease risk but are insufficient to actually cause a specific disorder.Current empirical and theoretical data support this hypothesis, although there remains great uncertainty as to the number of the underlying risk factors and their specific effect sizes.In this context, it is noteworthy that even recent genetic advances in the study of complex diseases such as AD or diabetes likely only represent the most obvi-ous, most extreme cases of the underlying risk spectrum (Figure 1; ref.2).In AD, for instance, rare, fully penetrant autosomal dominant mutations in 3 genes (i.e.APP, PSEN1, and PSEN2) have been shown to cause the disease, while a common, incompletely penetrant susceptibility variant (i.e., ε4 in APOE; see below) significantly increases the risk for AD.The identification of these genes early in the study of AD genetics was possible due to the combination of several favorable circumstances, such as the presence of multiple independent mutations in the same locus and the availability of extended, multigenerational pedigrees for DNA genotyping and sequencing (in the case of PSEN1) or a large attributable fraction to the overall genetic variance, resulting from relatively high allele frequency and pronounced effect size (in the case of APOE).However, identification of disease genes that make smaller overall contributions to the genetic spectrum (because of only few mutational events; e.g., PSEN2), or risk factors with smaller effect sizes (i.e.odds ratios [ORs] ranging between 2 and 3), will require much larger samples and possibly more sensitive and efficient analytic tools to enable consistent detection across study populations (2).Additional, and commonly cited, problems in finding complex disease genes beyond the most obvious are multiple testing, publication bias, and questionable replication (3-5).Multiple testing can be placed under the larger category of "avoidable false positive" findings, which are also caused by testing insufficiently sized samples, using inappropriate matching of cases versus controls, stratifying populations, and choosing inadequate analysis strategies, etc. Publication bias, on the other hand, which indicates the higher a priori likelihood of a positive finding being published as opposed to a negative one, may have been a possible source of serious bias in the early days.However, there is only relatively little empirical evidence that publication bias actually represents a common or significant source of error in current publications investigating the genetics of a number of disorders (e.g., refs.6-12).The sheer number of publications in the AD gene
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated levels of Amyloid-β (Aβ) peptide initiates a cascade of events that ultimately result in Alzheimer’s disease (AD) [1–4].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 4×
“The most frequently involved gene in recessive parkinsonism is parkin (PRKN) on chromosome 6q25 (33, 41), which causes nearly half of all early-onset PD cases.”
BackgroundInfluentialGoate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 5×
“In AD, for instance, rare, fully penetrant autosomal dominant mutations in 3 genes (i.e. APP, PSEN1, and PSEN2) have been shown to cause the disease, while a common, incompletely penetrant susceptibility variant (i.e., ε4 in APOE; see below) significantly increases the risk for AD.”
BackgroundInfluentialα-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · cited 1×
“AD APP (15) Aβ precursor protein 21q21 Dominant Altered Aβ production (Aβ42/Aβ40 ratio ↑) and aggregation AD APOE (21, 22) Apolipoprotein E 19q13 Risk factor Unknown (Aβ aggregation? lipid metabolism?) AD PSEN1 (16) Presenilin 1 14q24 Dominant Altered Aβ production (Aβ42/Aβ40 ratio ↑) AD PSEN2 (17, 18) Presenilin 2 1q…”
BackgroundCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · cited 9×
“In AD, for instance, rare, fully penetrant autosomal dominant mutations in 3 genes (i.e. APP, PSEN1, and PSEN2) have been shown to cause the disease, while a common, incompletely penetrant susceptibility variant (i.e., ε4 in APOE; see below) significantly increases the risk for AD.”
BackgroundInfluential
Research works printed but not linked: 1
- [92]Prusiner, S.B. 1998. Prions. Proc. Natl. Acad. Sci. U. S. A. 95 :13363-13383.
Cited by
Items 201–300 of 678
Chronic Bacterial and Viral Infections in Neurodegenerative and Neurobehavioral Diseases
Nicolson, G. L. (2008) · Laboratory Medicine · doi:10.1309/96m3bwyp42l11bfu · Cited by 45
“They are characterized by molecular and genetic changes in nerve cells that result in nerve cell degeneration and ultimately nerve dysfunction and death, resulting in neurological signs and symptoms and dementia.(1,2) In addition to neu-”
Alzheimer’s Genetics in the GWAS Era: A Continuing Story of ‘Replications and Refutations’
Bertram, L. (2011) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-011-0193-z · Cited by 46
“This strategy was highly successful for a large number of Mendelian diseases, including many common neurodegenerative disorders [ 6 ].”
BackgroundResultInfluentialSelf-citationPorphyromonas gingivalis: a potential trigger of neurodegenerative disease
Huang, Z., Hao, M., Shi, N., Wang, X., Lin, Y., Yuan, H., & Wang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1482033 · Cited by 53
“These diseases are commonly associated with aging, and their occurrence rises as people get older (34).”
Metals and cholesterol: two sides of the same coin in Alzheimer’s disease pathology
Wong, B. X. W., Hung, Y. H., Bush, A. I., & Duce, J. A. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00091 · Cited by 44
“Approximately 8–10% of the population over the age of 65 have AD, and its prevalence doubles every 5 years thereafter (Cummings, 2004; Bertram and Tanzi,2005).”
BackgroundTransgenic animal models of neurodegeneration based on human genetic studies
Harvey, B. K., Richie, C. T., Hoffer, B. J., & Airavaara, M. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-010-0476-6 · Cited by 39
“Although APOE-E4 remains the highest risk factor identified for sporadic AD (Bertram and Tanzi 2005), no transgenic animals based on APOE-E4 allele have produced an AD phenotype.”
Zhao, C., Lv, C., Li, H., Du, S., Liu, X., Li, Z., Xin, W., & Zhang, W. (2016) · PLOS ONE · doi:10.1371/journal.pone.0152551 · Cited by 39
Panahi, Y., Rajaee, S. M., Johnston, T. P., & Sahebkar, A. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26536 · Cited by 41
“Several examples of this problem include as multiple sclerosis (MS), Parkinson’s disease (PD), Huntington’s chorea (HC), and Alzheimer’s disease (AD), which are all categorized as neurodegenerative diseases (NDs).(2) Recent accurate estimates of the incidence of various forms of NDs demonstrate an alarming increase.”
BackgroundEmerging role of microRNAs in diagnosis and treatment of various diseases including ovarian cancer
Shah, P. P., Hutchinson, L., & Kakar, S. S. (2009) · Journal of Ovarian Research · doi:10.1186/1757-2215-2-11 · Cited by 41
“Studies have shown that gene defects play an important role in the pathogenesis of neurodegenerative diseases such as Parkinson's, Alzheimer's, and Huntington's [6].”
BackgroundBhat, M. A., Ahmad, K., Khan, M. S., Bhat, M. A., Almatroudi, A., Rahman, S., & Jan, A. T. (2020) · Biomolecules · doi:10.3390/biom10060863 · Cited by 44
The Effects of SIRT1 on Alzheimer's Disease Models
Donmez, G. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/509529 · Cited by 38
“APP is cleaved in two sequential steps by the β- and γ-secretases to generate Aβ 1–40 and 1–42 amyloid peptides, respectively [3].”
BackgroundZhang, Q., Yu, J., Wang, P., Chen, W., Wu, Z., Jiang, H. F., & Tan, L. (2010) · Brain Research · doi:10.1016/j.brainres.2010.10.074 · Cited by 39
“However, to date, only the ε4 allele of the apolipoprotein E gene (APOE ε4) has been definitively associated with late-onset Alzheimer's disease (LOAD) (Tanzi and Bertram, 2005), which represents the vastmajority of all AD cases.”
BackgroundAlzheimer’s disease: diagnostics, prognostics and the road to prevention
Grossman, I., Lutz, M. W., Crenshaw, D. G., Saunders, A. M., Burns, D. K., & Roses, A. D. (2010) · EPMA Journal · doi:10.1007/s13167-010-0024-3 · Cited by 37
Gene panels and primers for next generation sequencing studies on neurodegenerative disorders
Giau, V. V., An, S. S. A., Bagyinszky, E., & Kim, S. (2015) · Molecular & Cellular Toxicology · doi:10.1007/s13273-015-0011-9 · Cited by 40
Kuchimanchi, M., Monine, M. I., Muralidharan, K. K., Woodward, C. N., & Penner, N. A. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12538 · Cited by 42
“Parkinson’s disease (PD) is one of the most common neurodegenerative diseases in the world and it is clinically diagnosed by the constellation of rest tremor, bradykinesia, and cogwheel rigidity.(1) In the United States alone, its estimated prevalence ranges from 430,000 to ~ 1 million,(2) and its economic burden was…”
BackgroundNeurodegeneration: Diagnosis, Prevention, and Therapy
Poddar, M. K., Chakraborty, A., & Banerjee, S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.94950 · Cited by 51
Role of Microglia in Regulating Cholesterol and Tau Pathology in Alzheimer’s Disease
Nanjundaiah, S., Chidambaram, H., Chandrashekar, M., & Chinnathambi, S. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00883-6 · Cited by 36
From a Highly Disordered to a Metastable State: Uncovering Insights of α-Synuclein
Cote, Y., Delarue, P., Scheraga, H. A., Senet, P., & Maisuradze, G. G. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00446 · Cited by 38
“Therefore, to define the time averages 〈···〉 of the dihedral angles in Equation (2), we built two discrete time series Sγ and Sδ from the successive dihedral angle displacements (between two snapshots) Δγ and Δδ respectively.”
MethodInfluentialIn Vitro Blood–Brain Barrier-Integrated Neurological Disorder Models Using a Microfluidic Device
Choi, J., Santhosh, M., & Choi, J.-W. (2019) · Micromachines · doi:10.3390/mi11010021 · Cited by 37
Kermanshahi, S., Ghanavati, G., Mesrabadi, M. A., Gholami, M., Ulloa, L., Motaghinejad, M., & Safari, S. (2020) · Neurochemical Research · doi:10.1007/s11064-020-03134-8 · Cited by 39
Chen, Z., Yu, Y., Han, Y., & Wang, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.937333 · Cited by 43
Mitophagy’s impacts on cancer and neurodegenerative diseases: implications for future therapies
Huang, J. B., Pham, V. T., Fu, S., Huang, G., Liu, Y., & Zheng, L. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01727-w · Cited by 45
“PD manifests largely as a progressive movement disorder characterized by the presence of cytoplasmic inclusions comprised of insoluble protein aggregates and a loss of dopaminergic neurons in the substantia nigra [50].”
The role of magnetic resonance imaging in the diagnosis of Parkinson's disease: a review
Al‐Radaideh, A., & Rababah, E. M. (2016) · Clinical Imaging · doi:10.1016/j.clinimag.2016.05.006 · Cited by 46
Li, S., Chen, Y., Sun, D., Bai, R., Gao, X., Yang, Y., Sheng, J., & Xu, Z. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0396-7 · Cited by 36
“It is generally accepted that gene defects play a major role in the etiology and pathogenesis of these disorders [1], and nearly 60 genes have been identified, such as β-amyloid precursor protein in AD, α-synuclein in PD, microtubule-associated protein tau in FTLD, and superoxide dismutase 1 in ALS [2] .”
BackgroundSilk fibroin nanoscaffolds for neural tissue engineering
Boni, R., Ali, A., Giteru, S. G., Shavandi, A., & Clarkson, A. N. (2020) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-020-06422-5 · Cited by 41
Delivery Platforms for CRISPR/Cas9 Genome Editing of Glial Cells in the Central Nervous System
Meneghini, V., Peviani, M., Luciani, M., Zambonini, G., & Gritti, A. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.644319 · Cited by 41
“Almost 58% of the genetic variants in human diseases are associated with point mutations, including mendeliansegregating genes and single-nucleotide polymorphisms (SNPs) associated with genetic risk factors in neurodegenerative disorders (Bertram and Tanzi, 2005).”
BackgroundAyyadevara, S., Ganne, A., Balasubramaniam, M., & Reis, R. J. S. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00791-8 · Cited by 41
“Known risk factors for neurodegenerative diseases are increasing age, oxidative stress, inflammation, hypertension, genetic polymorphism, food habits, depression, and environmental factors (Bertram and Tanzi 2005).”
BackgroundInfluentialHuman prion diseases and the prion protein – what is the current state of knowledge?
Nafe, R., Arendt, C. T., & Hattingen, E. (2023) · Translational Neuroscience · doi:10.1515/tnsci-2022-0315 · Cited by 41
“This was also addressed in a report from 2005 concerning evidence of an overrepresentation of the M allele at position 129 of PrP C in patients with Alzheimer ’ s disease (AD) [65].”
BackgroundKetelaar, M. E., Hofstra, R. M. W., & Hayden, M. R. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2011.01795.x · Cited by 35
“Although familial aggregation of phenotype is a prominent feature of most neurodegenerative disorders and has been of great value in the discovery of genetic contribution, numerous examples of lack of expected correlation between genotype and phenotype are apparent (1, 2).”
BackgroundAnalysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease
Fernández, M. V., Kim, J. H., Budde, J., Black, K., Medvedeva, A., Saef, B. A., Deming, Y. K., Del‐Aguila, J. L., Ibáñez, L., Dube, U., et al. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1007045 · Cited by 37
“The rare familial forms have been key to our understanding of each disease’s pathology; these are well characterized by a dominant pathologic protein aggregate in a specific location within the nervous system caused by the impairment of a specific set of genes [2].”
BackgroundInfluentialCloyd, R., Koren, S. A., & Abisambra, J. F. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00403 · Cited by 36
Crosstalk between Different DNA Repair Pathways Contributes to Neurodegenerative Diseases
Gupta, S., You, P., SenGupta, T., Nilsen, H. L., & Sharma, K. (2021) · Biology · doi:10.3390/biology10020163 · Cited by 41
Wang, X., Li, M., Cao, Y., Wang, J., Zhang, H., Zhou, X., Li, Q., & Wang, L. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.004 · Cited by 35
“In recent years, the incidence of neurodegenerative disease increased significantly worldwide (Bertram and Tanzi, 2005; Qiu et al., 2009).”
BackgroundImproving drug delivery technology for treating neurodegenerative diseases
Choonara, Y. E., Kumar, P., Modi, G., & Pillay, V. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1162152 · Cited by 35
“The fact that genetic screening may be used to predict individuals destined to acquire the disease makes treatment strategies and formulation approaches for HD very interesting.[98] It has been demon-”
BackgroundFamilial risks for amyotrophic lateral sclerosis and autoimmune diseases
Hemminki, K., Li, X., Sundquist, J., & Sundquist, K. (2008) · Neurogenetics · doi:10.1007/s10048-008-0164-y · Cited by 36
“The dominantly inherited SOD1 gene is thought to explain 10–20% of familial ALS, and also, other rarer gene variants have been identified, including TARDBP, DPP6, and others discussed in the cited papers [6–10].”
BackgroundExpression of A2V-mutated Aβ in Caenorhabditis elegans results in oligomer formation and toxicity
Diomede, L., Fede, G. D., Romeo, M., Bagnati, R., Ghidoni, R., Fiordaliso, F., Salio, M., Rossi, A., Catania, M., Paterlini, A., et al. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.10.024 · Cited by 35
Sun, Y., Islam, S., Michikawa, M., & Zou, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031757 · Cited by 42
“This process leads to the generation of A β peptides, a hallmark feature in AD pathology [3].”
BackgroundGross, M., Sheinin, A., Nesher, E., Tikhonov, T., Baranes, D., Pinhasov, A., & Michaelevski, I. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.02.015 · Cited by 32
“Thus, accumulating evidence hints that behavioral disturbances accompanying neurodegenerative and affective disorders may share common molecular mechanisms (Bertram and Tanzi, 2005; Rodriguez and Verkhratsky, 2011).”
BackgroundThe Role of Viruses in Neurodegenerative and Neurobehavioral Diseases
Karim, S., Mirza, Z., Kamal, M. A., Abuzenadah, A. M., Azhar, E. I., Al-Qahtani, M., Damanhouri, G., Ahmad, F., Gan, S. H., & Sohrab, S. S. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152731307141015122638 · Cited by 34
“In addition, chronic viral infections, nutritional deficiencies, exposure to environmental toxins such as heavy metals, autoimmune responses, vascular diseases, head trauma, accumulation of fluid in the brain, and changes in neurotransmitter concentrations are reported to be involved in the pathogenesis of various neu…”
BackgroundCarboni, E., Nicolas, J., Töpperwien, M., Stadelmann, C., Lingor, P., & Salditt, T. (2017) · Biomedical Optics Express · doi:10.1364/boe.8.004331 · Cited by 32
Chen, M., Wang, M., Wang, Q., Neff, R. A., Wang, E., Shen, Q., Reddy, J. S., Wang, X., Allen, M., Ertekin‐Taner, N., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12507 · Cited by 34
Rahman, B., Meiser, B., Sachdev, P. S., Barlow-Stewart, K. K., Otlowski, M. F. A., Zilliacus, E. M., & Schofield, P. R. (2012) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2011.0300 · Cited by 40
“Autosomal dominantly inherited AD accounts for * 1%– 5% of all cases (Bertram and Tanzi, 2005).”
Ahmed, S. S. S. J., Husain, R. S. A., Kumar, S., & Ramakrishnan, V. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.07.041 · Cited by 32
Janaszewska, A., Klajnert‐Maculewicz, B., Marcinkowska, M., Duchnowicz, P., Appelhans, D., Grasso, G., Deriu, M. A., Danani, A., Cangiotti, M., & Ottaviani, M. F. (2017) · Nano Research · doi:10.1007/s12274-017-1734-9 · Cited by 34
“Currently, the most prevalent neurodegenerative disorder is Alzheimer’s disease (AD), followed by Parkinson’s disease (PD), and relatively rare disorders such as Huntington disease (HD) and amyotrophic lateral sclerosis (ALS) [1].”
BackgroundTherapeutic trial design for frontotemporal dementia and related disorders
Desmarais, P., Rohrer, J. D., Nguyen, Q. D., Herrmann, N., Stuss, D. T., Lang, A. E., Boxer, A. L., Dickerson, B. C., Rosen, H., van Swieten, J. C., et al. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-318603 · Cited by 33
Moll, L., & Schubert, M. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/384094 · Cited by 31
“Thus, alterations of insulin levels and insulin-mediated signals/transcription might be an interesting candidate to explain the association of obesity and dementia.”
BackgroundTalwar, P., Gupta, R., Kushwaha, S. S., Agarwal, R., Saso, L., Kukreti, S., & Kukreti, R. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180419124508 · Cited by 33
Sefiani, A., & Geoffroy, C. G. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.682259 · Cited by 35
Serine phosphorylation and arginine methylation at the crossroads to neurodegeneration
Basso, M., & Pennuto, M. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.05.003 · Cited by 32
Role of P2Y receptors in astrocyte physiology and pathophysiology
Lohr, C. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109311 · Cited by 31
Genetic Modifiers in Neurodegeneration
Jain, N., & Chen-Plotkin, A. S. (2018) · Current Genetic Medicine Reports · doi:10.1007/s40142-018-0133-1 · Cited by 30
Kim, K. H., Lee, S., Shin, J., Hwang, J.-T., Jeon, H. N., & Bae, H. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00080 · Cited by 33
Novel therapeutic approaches to target neurodegeneration
de la Fuente, A. G., Pelucchi, S., Mertens, J., Luca, M. D., Mauceri, D., & Marcello, E. E. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16078 · Cited by 33
A TAP2 genotype associated with Alzheimer's disease in APOE4 carriers
Bullido, M. J., Martínez-García, A., Artiga, M. J., Aldudo, J., Sastre, I., Gil, P., Coria, F., Muñoz, D. G., Hachinski, V., Frank, A., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.011 · Cited by 36
“In particular, homozygosity for AP2687C in carriers of the APOE4 leads to a risk comarable to that reported for APOE4 homozygosity [4].”
BackgroundGenetics and biology of Alzheimer's disease and frontotemporal lobar degeneration.
Galimberti, D., & Scarpini, E. A. (2010) · PubMed Central · Cited by 44
Diagnosis of Alzheimer's disease in Brazil: Supplementary exams
Caramelli, P., Teixeira, A. L., Buchpiguel, C. A., Lee, H. W., LIVRAMENTO, J. A., Fernandez, L. L., & Anghinah, R. (2011) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642011dn05030004 · Cited by 39
Sivachenko, A., Gordon, H. B., Kimball, S. S., Gavin, E., Bonkowsky, J. L., & Letsou, A. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.022244 · Cited by 35
“The mode of inheritance of SLC27a6 294 -associated neurodegenerative disease seems to be autosomal dominant, as is the case for several well-documented neurodegenerative conditions in humans (Bertram and Tanzi, 2005).”
Nutrition Education Programs for Adults with Neurological Diseases Are Lacking: A Scoping Review
Russell, R., Black, L. J., & Begley, A. M. (2022) · Nutrients · doi:10.3390/nu14081577 · Cited by 31
“Common neurological diseases include Alzheimer’s disease and other dementias, epilepsy, Huntington’s disease, motor neurone disease, multiple sclerosis, Parkinson’s disease, and stroke [1,3,4], and they affect up to one billion people worldwide [2].”
BackgroundGenetics of psychosis of Alzheimer disease
Shah, C., DeMichele‐Sweet, M. A. A., & Sweet, R. A. (2016) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32413 · Cited by 31
Yang, J., Yang, Y., & Chen, S. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116889 · Cited by 30
Mushroom Polysaccharides as Potential Candidates for Alleviating Neurodegenerative Diseases
Jiang, X., Li, S., Feng, X., Li, L., Hao, J., Wang, D., & Wang, Q. (2022) · Nutrients · doi:10.3390/nu14224833 · Cited by 31
Morgan, C. D., & Murphy, C. (2012) · Behavioral and Brain Functions · doi:10.1186/1744-9081-8-37 · Cited by 33
Alvarez, V., Corao, A. I., Alonso-Montes, C., Sánchez-Ferrero, E., De Mena, L., Morales, B., García-Castro, M., & Coto, E. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-13305 · Cited by 27
“Genetically, AD is a complex and heterogeneous disease [8,19,34].”
Copy Number Variants in miR-138 as a Potential Risk Factor for Early-Onset Alzheimer’s Disease
Boscher, E., Husson, T., Quenez, O., Laquerrière, A., Marguet, F., Cassinari, K., Wallon, D., Martinaud, O., Charbonnier, C., Nicolas, G., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180940 · Cited by 29
“-secretase [5, 6].”
Hou, Z., Sun, L., Jiang, Z., Zeng, T., Wu, P., Huang, J., Liu, H., & Xiao, P. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155374 · Cited by 31
Briffa, M., Ghio, S., Neuner, J., Gauci, A. J., Cacciottolo, R., Marchal, C., Caruana, M., Cullin, C., Vassallo, N., & Cauchi, R. J. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.11.058 · Cited by 29
Kim, K., Kim, M. H., Lee, J., Jeon, H. N., Kim, S., & Bae, H. (2019) · Toxins · doi:10.3390/toxins11060358 · Cited by 29
“Parkinson’s disease (PD) is an age-related neurodegenerative disorder characterized by the progressive loss of dopaminergic (DA) neurons in the substantia nigra [1].”
BackgroundAlzheimer'S Disease: Advances In Genetics, Molecular And Cellular Biology
Sisodia, S. S., & Tanzi, R. E. (2007) · Cited by 30
Neurodegenerative Diseases: New Hopes and Perspectives
Bhat, M. A., & Dhaneshwar, S. S. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230907093451 · Cited by 31
Home care program for patients at high risk of hospitalization.
Levine, S., Steinman, B. A., Attaway, K., Jung, T., & Enguidanos, S. M. (2012) · PubMed · Cited by 26
Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases
McAlary, L., Plotkin, S. S., & Cashman, N. R. (2019) · CNS Drugs · doi:10.1007/s40263-019-00657-9 · Cited by 28
HMGB1 Mediates Paraquat-Induced Neuroinflammatory Responses via Activating RAGE Signaling Pathway
Huang, M., Guo, M., Wang, K., Wu, K., Li, Y., Tian, T., Wang, Y., Yan, W., Zhou, Z., & Yang, H. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-00148-1 · Cited by 28
Umoh, I. O., Reis, H. J., & de Oliveira, A. C. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25053044 · Cited by 31
Guan, Y., Li, Y., Zhao, G., & Li, Y. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.03.031 · Cited by 28
Alpha-Synuclein-Specific Regulatory T Cells Ameliorate Parkinson’s Disease Progression in Mice
Park, S.-Y., Yang, H., Kim, S., Yang, J., Go, H., & Bae, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015237 · Cited by 29
“PD is characterized by the loss of dopaminergic neurons in the SN [22].”
BackgroundPreclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson’s Disease
Perez, X. A. (2015) · Neuropsychology Review · doi:10.1007/s11065-015-9303-z · Cited by 27
“Parkinson’s disease (PD) is the second most common neurodegenerative disorder among the population over 65 years of age worldwide (Bertram and Tanzi 2005).”
BackgroundAlzheimer's disease: epidemiology
Mayeux, R. P. (2008) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)01218-3 · Cited by 27
Effects of Acute Exposure to Aluminum on Cognition in Humans
Molloy, D. W., Standish, T. I. M., Nieboer, E., Turnbull, J. D., Smith, S. D., & Dubois, S. J. (2007) · Journal of Toxicology and Environmental Health · doi:10.1080/15287390701551142 · Cited by 30
“The latter allele constitutes the most consistent genetic risk factor for late-onset AD, with estimated relative risks of around 3 and 15 for heterozygous and homozygous carriers respectively ( Bertram & Tanzi, 2004 , 2005 ).”
BackgroundEimer, W. A., Rodriguez, A. S., DeFao, M. T., Ehricke, S., Park, J., Kumar, D. K. V., Shanmugam, N. K. N., Singh, S., Sawhney, T., Moir, R. D., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02157-0 · Cited by 34
Delivery of neurotrophic factors in the treatment of age-related chronic neurodegenerative diseases
Padmakumar, S., Taha, M. S., Kadakia, E., Bleier, B. S., & Amiji, M. M. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1727443 · Cited by 26
“[3], spanning from movement impairments to cognitive decline and psychiatric disorders.”
BackgroundMapping genetic modulators of amyloid plaque deposition in TgCRND8 transgenic mice
Sebastiani, G., Krzywkowski, P., Dudal, S., Yu, M. W. N., Paquette, J., Malo, D., Gervais, F., & Tremblay, P. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl157 · Cited by 30
“Collectively, these four genes account for less than 50% of the genetic variance seen in AD (12).”
BackgroundWang, Y. A., Kammenga, J. E., & Harvey, S. C. (2017) · Human Genomics · doi:10.1186/s40246-017-0108-4 · Cited by 23
“Hence, the genetics of these diseases is considered “complex” based on the heterogeneity in pathology and the disease polygenicity [8].”
BackgroundHasan, U., & Singh, S. K. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9068-9_1 · Cited by 25
Angelopoulou, E., Koros, C., Hatzimanolis, A., Stefanis, L., Scarmeas, N., & Papageorgiou, S. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052645 · Cited by 26
“Alzheimer’s disease (AD) is the most common cause of dementia, constituting 60–70% of all cases [2].”
BackgroundInfluentialPredictive Precision Medicine: Towards the Computational Challenge
Tuena, C., Semonella, M., Fernández‐Álvarez, J., Colombo, D., & Cipresso, P. (2019) · Springer eBooks · doi:10.1007/978-3-030-27994-3_5 · Cited by 31
“Indeed, neurodegenerative diseases have specific gene profiles (Bertram and Tanzi 2005).”
BackgroundMitochondrial Regulatory Pathways in the Pathogenesis of Alzheimer’s Disease
Adiele, R. C., & Adiele, C. A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150967 · Cited by 23
“Mutations in A PP, presenilin-1, and presenilin-2 have been implicated as major risk factors in AD and typically associated with early onset familial AD isoform [77, 101].”
Genetic Epidemiology of Alzheimer Disease
Mayeux, R. P. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200607001-00008 · Cited by 30
“The genetic influences on AD are important and complex.(7,8) Over the last 2 decades variants in 4 genes have been firmly implicated in the cause or risk of this disease (Table 1).”
BackgroundRecent Advancement of Pyrazole Scaffold Based Neuroprotective Agents: A Review
Pottoo, F. H., Joseph, A., Das, S., Akbar, S., Ahmed, B., Dewangan, R. P., Iqubal, M. K., Iqubal, A., & Chawla, P. A. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210602152308 · Cited by 22
The GRP78-PERK axis contributes to memory and synaptic impairments in Huntington's disease R6/1 mice
Espina, M., Franco, N. D., Brañas-Navarro, M., Rodríguez-Navarro, I., Brito, V., López-Molina, L., Costas‐Insua, C., Guzmán, M., & Ginés, S. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106225 · Cited by 30
“However, most share an archetypical pathological attribute: aberrant aggregation of misfolded proteins that eventually triggers endoplasmic reticulum (ER) stress (Aguzzi and O’Connor, 2010; Bertram and Tanzi, 2005; Soto, 2003).”
BackgroundWu, X., Sun, J., & Li, L. (2013) · Neuroscience Bulletin · doi:10.1007/s12264-013-1345-8 · Cited by 23
Liu, Q., Wang, S., & Ding, K. (2017) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(17)30093-6 · Cited by 24
Þórðardóttir, S., Rodriguez‐Vieitez, E., Almkvist, O., Ferreira, D., Saint‐Aubert, L., Ståhlbom, A. K., Thonberg, H., Schöll, M., Westman, E., Wall, A. E., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0374-y · Cited by 23
“To date, over 240 mutations in the PSEN1 gene have been reported [20], most of which are pathogenic and lead to FAD.”
InfluentialIncreased severity over generations of Charcot-Marie-Tooth disease type 1A
Steiner, I., Gotkine, M., Steiner‐Birmanns, B., Biran, I., Silverstein, S. M., Abeliovich, D., Argov, Z., & Wirguin, I. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0693-1 · Cited by 22
“Two notable examples are myotonic dystrophy and Huntington’s disease (HD) where anticipation is more evident regarding age at onset [21,22].”
BackgroundFamilial Risks for Main Neurological Diseases in Siblings Based on Hospitalizations in Sweden
Hemminki, K., Sundquist, K., & Li, X. (2006) · Twin Research and Human Genetics · doi:10.1375/183242706778024991 · Cited by 21
“The noted association between Alzheimer's and Parkinson's diseases may be due to related conditions, such as Lewy body dementia and frontotemporal dementia, both of which may show an Alzheimer's type of dementia and Parkinsonian features (Bertram & Tanzi, 2005; Ropper & Brown, 2005).”
BackgroundInfluentialMicroarray Analysis of VEGF-C Responsive Genes in Human Lymphatic Endothelial Cells
Yong, C., Bridenbaugh, E. A., Zawieja, D. C., & Swartz, M. A. (2005) · Lymphatic Research and Biology · doi:10.1089/lrb.2005.3.183 · Cited by 23
Testing synthetic amyloid-β aggregation inhibitor using single molecule atomic force spectroscopy
Hane, F. T., Lee, B. Y., Petoyan, A., Rauk, A., & Leonenko, Z. (2013) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2013.10.060 · Cited by 20
“AD is a complex disease associated with a number of potential factors including aging (Bertram and Tanzi, 2005), genetics (Bertram and Tanzi, 2005), metals dyshomeostasis (Bush and Tanzi, 2008), protein–lipid interactions (DiPaolo and Kim, 2011), vascular disorders (Roy and Rauk, 2005), and loss of…”
BackgroundApo E4 Alleles and Impaired Olfaction as Predictors of Alzheimer’s Disease
Misiak, M., Hipolito, M. S., Ressom, H. W., Obisesan, T. O., Manaye, K. F., & Nwulia, E. A. (2017) · Clinical and Experimental Psychology · doi:10.4172/2471-2701.1000169 · Cited by 23
“Inheritance of a single ApoE ε4 variant increases a person’s risk of developing AD by a factor of three in men and four in women, and having two copies of the ε4 allele increases risk by up to 15-fold compared to persons without the ε4 variant [4,5].”
BackgroundYeast as a model to study protein misfolding in aged cells
Gregorio, S. E. D., & Duennwald, M. L. (2018) · FEMS Yeast Research · doi:10.1093/femsyr/foy054 · Cited by 26
Ortelli, P., Ferrazzoli, D., Bera, R., Caremani, L., Giladi, N., Maestri, R., & Frazzitta, G. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-171247 · Cited by 24
“Parkinson’s disease (PD) is the second most common neurodegenerative disorder [1].”
Gottlieb, C. D., Thompson, A. C. S., Ordureau, A., Harper, J. W., & Kopito, R. R. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.009654 · Cited by 23
“Instead, most conformational diseases arise from the production of a single, conformationally impaired, aggregation-prone protein, such as the mutant proteins linked to genetic diseases (39).”
BackgroundLiterature-related discovery: common factors for Parkinson’s Disease and Crohn’s Disease
Kostoff, R. N. (2014) · Scientometrics · doi:10.1007/s11192-014-1298-3 · Cited by 23
Metadata
- Authors
- Bertram, L.
- Affiliations
- Harvard University (US)
- Corresponding author
- Bertram, L.
- ORCID
- Bertram, L.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-06-01
- Volume
- 115
- Issue
- 6
- Pages
- 1449-1457
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1137006
- OpenAlex
- W2110054485
- Cited by
- 680
- References
- 106
- Citations by year
- 2026: 17 · 2025: 29 · 2024: 40 · 2023: 48 · 2022: 48 · 2021: 40 · 2020: 44 · 2019: 37 · 2018: 46 · 2017: 41 · 2016: 36 · 2015: 20 · 2014: 25 · 2013: 25 · 2012: 34
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Association
- Massachusetts General Hospital
- National Alliance for Research on Schizophrenia and Depression
- Deutsche Forschungsgemeinschaft
- National Institute on Aging
- National Institute of Mental Health
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- neurodegenerative diseases, genetic epidemiology, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington's disease, prion disease, common disease-common variant hypothesis, complex disease genetics, familial aggregation, genetic risk factors, single nucleotide polymorphisms, gene-environment interaction, genetic heterogeneity, pathogenesis, amyloid precursor protein, alpha-synuclein, tau protein
- MeSH terms
- Chromosome Mapping, Nerve Degeneration, Molecular Epidemiology, Neurodegenerative Diseases, Genetic Predisposition to Disease, Physical Chromosome Mapping
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.